Abiopharma

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

FuelCell Energy Secures $49 Million in EXIM Financing to Advance U.S. Clean Energy Exports

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Twin Disc, Inc. Joins Russell 2000® and Russell 3000® Indexes

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Dyadic Expands IP Protection and Business Development Activities in Japan

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Dyadic Expands IP Protection and Business Development Activities in Japan

Net Asset Value(s)

Private placement of 430,835 to employees, officers and CEO